Abstract
Objective
Helicobacter pylori is considered as an important etiologic factor in pathogenesis of peptic ulcer disease, chronic gastritis and gastric cancer. To eradicate this micro-organism, numerous regimens containing various antimicrobial agents have been suggested. However, H pylori antimicrobial resistance is a leading factor to treatment failure and recurrence of the disease. The aim of the study was to evaluate the prevalence of H pylori resistance to metronidazole, clarithromycin, tetracycline, amoxicillin, erythromycin and furazolidone in authors pediatric patients.
Methods
Antral biopsy of all pediatric patients with negative history of receiving anti-H pylori regimen and endoscopic findings of nodular gastritis or peptic ulcer without previous history of NSAID consumption, burning and trauma were performed for H pylori histology, urease test and culture. All positive cultures were tested for antimicrobial susceptibility.
Results
Twenty four patients (14 male and 10 female) between 3.5 and 14 years of age were culture positive. 54.16% of the isolates were resistant to metronidazole, 8.33% to amoxicillin, 4.16% to erythromycin and 4.16% to clarithromycin. None of authors patients were resistant to tetracycline and furazolidone.
Conclusion
H. pylori antimicrobial resistance could be a major contributor to failure of H pylori eradication. Continuous prospective surveillance of H. Pylori is essential. Moreover, culture and antimicrobial susceptibility test is recommended for resistant cases after the first failure to therapy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Frenck RW Jr, Clemens J. Helicobacter in the developing world. Microbes Infect 2003; 5: 705–713.
Gottrand F, Turck D. Helicobacter pylori infection in children. Arch Pediatr 1995; 2: 573–579.
Brown LM. Helicobacter pylori: epidemiology and routs of transmission. Epidemiol Rev 2000; 22: 283–297.
Duck WM, Sobel J, Pruckler JM, Song Q, Swerdlow D, Friedman C et al. Antimicrobial resistance incidence and risk factors among Helicobacter pylori-infected persons, United States. Emerg Infect Dis 2004; 10: 1088–1094.
Labenz J. Consequences of Helicobacter pylori cure in ulcer patients. Baillieres Best Pract Res Clin Gastroenterol 2000; 14: 133–145.
Kalach N, Bergeret M, Benhamou PH, Dupont C, Raymond J. High levels of resistance to metronidazole and clarithromycin in Helicobacter pylori strains in children. J Clin Microbiol 2001; 39: 394–397.
Hoffman JSC, David R. Treatment of Helicobacter pylori. Curr Opin Gastroenterol 2001; 17: 30–34.
Adamek R J, Suerbaum S, Pfaffenbach B, Opferkuch W. Primary and acquired Helicobacter pylori resistance to clarithromycin, metronidazole, and amoxicillin—influence on treatment outcome. Am J Gastroenterol 1998; 93: 386–389.
Kim JJ, Reddy R, Lee M, Kim JG, El-Zaatari FA, Osato MS et al. Analysis of metronidazole, clarithromycin and tetracycline resistance of Helicobacter pylori isolates from Korea. J Antimicrob Chemother 2001; 47: 459–461.
Tolia V, Brown W, El-Baba M, Lin CH. Helicobacter pylori culture and antimicrobial susceptibility from pediatric patients in Michigan. Pediatr Infect Dis J 2000; 19: 1167–1171.
Wolle K, Leodolter A, Malfertheiner P, Konig W. Antibiotic susceptibility of Helicobacter pylori in Germany: stable primary resistance from 1995 to 2000. J Med Microbiol 2002; 51: 705–709.
Shashidhar H, Peters JM, Lin CH, Rabah R, Thomas R, Tolia V. A prospective trial of lansoprazole triple therapy for pediatric Helicobacter pylori infection. J Pediatr Gastroenterol Nutr 2000; 30: 276–282.
van der Wouden EJ, van Zwet AA, Vosmaer GD, Oom JA, de Jong A, Kleibeuker JH. Rapid increase in the prevalence of metronidazole-resistant Helicobacter pylori in the Netherlands. Emerg Infect Dis 1997; 3: 385–389.
Sisson G, Jeong JY, Goodwin A, Bryden L, Rossler N, Lim-Morrison S et al. Metronidazole activation is mutagenic and causes DNA fragmentation in Helicobacter pylori and in Escherichia coli containing a cloned H. pylori RdxA(+) (Nitroreductase) gene. J Bacteriol 2000; 182: 5091–5096.
Malaty HM, Kim JG, Kim SD, Graham DY. Prevalence of Helicobacter pylori infection in Korean children: inverse relation to socioeconomic status despite a uniformly high prevalence in adults. Am J Epidemiol 1996; 143: 257–262.
Cayla R. How to eradicate Helicobacter pylori? Gastroenterol Clin Biol 1996; 20(1 Pt 2): S119–S130.
Lin TKW, Cheng AFB, Sung JJY, Yiu PYL, Chung SSC. An increase in Helicobacter pylori strains resistant to metronidazole: a five-year study. Helicobacter 1996; 2: 185–187.
Fakheri H, Malekzadeh R, Merat S, Khatibian M, Fazel A, Alizadeh BZ et al. Clarithromycin vs. Furazolidone in quadruple therapy regimens for the treatment of Helicobacter pylori in a population with a high metronidazole resistance rate. Aliment Pharmacol Ther 2001; 15: 411–416.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fallahi, GH., Maleknejad, S. Helicobacter pylori culture and antimicrobial resistance in Iran. Indian J Pediatr 74, 127–130 (2007). https://doi.org/10.1007/s12098-007-0003-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12098-007-0003-4